Authors

Zhi Wang*, Jianhui Yan*, Jian Huang**, #

Departments

*Department of Geriatrics, Affiliated Hospital of Xiangnan College, Chenzhou, PR Chin - **Department of Emergency, Central Hospital, Chenzhou First People's Hospital, Chenzhou, PR China

Abstract

Objective: To study the efficacy of Medopa combined with Pramipexole in the treatment of Parkinson’s disease and its effect on serum inflammatory factors and receptors, oxidative stress level and epidermis growth factor.

Methods: 120 patients with Parkinson’s disease (PD) treated in our hospital from April 2018 to April 2019 were randomly divided into an observation group (n = 60) and a control group (n = 60). The patients in the control group were treated with Medopa, and the patients in the observation group were treated with Pramipexole on the basis of Medopa treatment. After 3 months of treatment, the therapeutic effect, serum inflammatory factors and receptors, oxidative stress level and epidermis growth factor were compared between the two groups.

Results: After treatment, the markedly effective rate, effective rate and total effective rate in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the serum IL-2, sIL-2R, IL-6 and sIL-6R levels of PD patients in the two groups showed a downward trend, the serum IL-2, sIL-2R, IL-6 and sIL-6R levels of PD patients in the observation group were lower than those of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of serum SOD, GSH-Px and GSH in the two groups of PD patients showed an upward trend, the levels of serum SOD, GSH-Px and GSH in the observation group were significantly higher than those in the control group, and the difference was statistically significant (P<0.05). The serum EGF level of PD patients after treatment in the two groups showed an upward trend, the serum EGF level of PD patients in the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05).

Conclusion: Medopa combined with Pramipexole is effective in the treatment of PD and can reduce the levels of serum IL-2, sIL-2R, IL-6 and sIL-6R, increase the level of serum SOD, GSH-Px and GSH, increase the level of serum EGF, and improve the prognosis of patients with PD.

Keywords

Medopa, pramipexole, parkinson’s disease, efficacy, inflammatory factors and receptors, oxidative stress level, epidermis growth factor.

DOI:

10.19193/0393-6384_2020_3_237